Preventing chlamydia comes down to a combination of barrier protection during sex, regular screening, and making sure sexual partners are tested and treated. Because 70 to 80% of women and up to 50% of men with chlamydia have no symptoms at all, you can’t rely on feeling fine as a sign you’re in the clear. Prevention has to be proactive.
How Chlamydia Spreads
Chlamydia is caused by the bacterium Chlamydia trachomatis, which infects the mucosal tissue lining the genitals, rectum, and throat. It spreads through vaginal, anal, and oral sex. You don’t need to have penetrative sex to transmit it; any contact between infected mucosal surfaces can pass the bacteria along. Ejaculation doesn’t have to occur for transmission to happen.
The infection can also pass from a pregnant person to their baby during delivery, potentially causing eye infections or pneumonia in the newborn. It does not spread through casual contact like hugging, sharing food, or using the same toilet seat.
Condoms Reduce Risk Significantly
Consistent condom use is one of the most effective tools for preventing chlamydia. In a study of people with known exposure to the infection, only 13.3% of consistent condom users tested positive for chlamydia, compared to 34.4% of those who used condoms inconsistently. That’s roughly a 90% reduction in the odds of infection when condoms are used every time.
The key word is “consistent.” Using a condom most of the time still leaves a significant gap in protection. External (male) condoms and internal (female) condoms both create a barrier over the mucosal surfaces where chlamydia takes hold. For oral sex, dental dams provide a similar barrier, though they’re used far less often in practice.
Condoms don’t eliminate risk entirely because chlamydia can infect areas a condom doesn’t cover, such as the throat during unprotected oral sex or the rectum during unprotected anal sex. Using the right barrier for each type of sexual contact matters.
Screening Catches What Symptoms Don’t
Given how often chlamydia produces no symptoms, routine screening is a critical layer of prevention. The CDC recommends annual chlamydia screening for all sexually active women under 25. Women 25 and older should be screened annually if they have risk factors: a new partner, more than one partner, a partner who has other partners, inconsistent condom use outside a mutually monogamous relationship, or a previous STI.
These same recommendations apply to transgender men and gender diverse people with a cervix. For men who have sex with men, screening at all sites of sexual contact (urethra, rectum, throat) is recommended at least annually, and more frequently for those with multiple partners.
Screening is a simple urine test or swab. If you test positive, you should be retested about three months after completing treatment. This isn’t to check whether the antibiotics worked; it’s to catch reinfection, which is common if a partner wasn’t treated at the same time.
Getting Partners Treated Prevents Reinfection
One of the most overlooked parts of chlamydia prevention is partner treatment. If you’re diagnosed and treated but your sexual partner isn’t, you’re likely to get reinfected the next time you have sex with them. This cycle is extremely common.
Expedited partner therapy, where your doctor provides a prescription or medication for your partner without requiring them to come in for a separate visit, reduces repeat infections by 20 to 29% compared to simply asking you to tell your partner to go see their own doctor. It also results in more partners actually completing treatment. EPT is legal in most U.S. states, and your provider can let you know if it’s available where you live.
If you’re in a relationship where both of you have been treated and retested, you can move forward without the back-and-forth cycle of reinfection. If you have multiple partners, notifying all recent partners gives them the chance to get tested and treated before spreading the infection further.
Doxycycline After Exposure (Doxy-PEP)
A newer prevention option is doxycycline post-exposure prophylaxis, commonly called doxy-PEP. This involves taking 200 mg of the antibiotic doxycycline as soon as possible, and within 72 hours, after having anal, oral, or vaginal sex. It’s designed for people at higher risk of STIs, particularly men who have sex with men and transgender women.
You should not take more than one dose in a 24-hour period, regardless of how many times you have sex that day. But you can take it as often as daily if your sexual activity calls for it. Your healthcare provider can determine whether doxy-PEP is appropriate for your situation and prescribe the right number of pills per dose.
This approach has shown strong effectiveness against chlamydia in clinical trials, though it’s not a replacement for condoms or screening. It’s an additional layer of protection, particularly useful for people who know they’ve had a high-risk exposure.
What Doesn’t Work
Antiseptic mouthwash has been studied as a possible way to prevent STIs transmitted through oral sex. In a randomized trial involving men who have sex with men, participants used Listerine Cool Mint daily and before and after sex for three months. The result: no significant reduction in STI rates compared to a placebo mouthwash. The researchers concluded that Listerine does not prevent STI acquisition, including chlamydia.
Washing or douching after sex also does not prevent chlamydia. Once the bacteria make contact with mucosal tissue, infection can establish quickly. No over-the-counter product, supplement, or home remedy has been shown to prevent chlamydia transmission.
Reducing Your Overall Risk
Beyond specific tools like condoms and screening, a few broader strategies lower your chlamydia risk. Having fewer sexual partners reduces the number of potential exposures. Mutual monogamy with a partner who has tested negative eliminates the risk almost entirely, as long as both of you were tested after any previous exposures.
Open communication with partners about testing and STI status, while sometimes uncomfortable, is one of the most practical things you can do. Asking a new partner when they were last tested, and sharing your own results, creates a foundation for informed decisions about protection.
For people who are pregnant, chlamydia screening early in pregnancy is standard practice because untreated infection can lead to complications during delivery and infection in the newborn. Retesting in the third trimester is recommended for those at continued risk.
Vaccines Are Still in Development
A chlamydia vaccine called CTH522 has completed two Phase 1 clinical trials. In both trials, the vaccine was safe and produced a strong immune response, with all participants developing at least a four-fold increase in antibodies against the bacteria. Some participants also developed detectable immune defenses in the vaginal tract after nasal booster doses. Side effects were mostly limited to injection-site soreness, headache, or mild fatigue.
Despite these encouraging results, the vaccine has not yet advanced to larger Phase 2 trials that would test whether it actually prevents infection in real-world conditions. A widely available chlamydia vaccine is still years away at best. For now, prevention depends entirely on the behavioral and medical strategies already available.